Thymosin Beta-4 Restores Blood Flow in Critically Ischemic Limbs by Growing New Blood Vessels

Thymosin β4 promoted angiogenesis in critical limb ischemia mice by activating the Notch/NF-κB pathway, boosting VEGF, angiopoietin-2, and blood vessel formation.

Lv, Shumin et al.·International journal of molecular medicine·2020·Moderate Evidenceanimal
RPEP-04973AnimalModerate Evidence2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
animal
Evidence
Moderate Evidence
Sample
N=animal study
Participants
Critical limb ischemia mouse model; HUVECs (human umbilical vein endothelial cells)

What This Study Found

Tβ4 promoted angiogenesis in CLI mice by upregulating VEGFA, Ang2, tie2, CD31, and α-SMA via Notch/NF-κB pathway activation, and reversed the effects of pathway inhibitors.

Key Numbers

Upregulated Ang2, tie2, VEGFA, CD31, alpha-SMA, N1ICD, Notch3, NF-kB, p-p65; reversed DAPT and BMS effects

How They Did This

Lentiviral Tβ4 overexpression in HUVECs and CLI mouse model; Notch inhibitor (DAPT) and NF-κB inhibitor (BMS) used for pathway confirmation; cell viability, tube formation, wound healing, Western blot, qPCR, immunofluorescence, immunohistochemistry.

Why This Research Matters

CLI affects millions and often leads to amputation. Tβ4's ability to grow new blood vessels through well-defined pathways makes it a strong candidate for limb salvage therapy.

The Bigger Picture

Therapeutic angiogenesis is a major goal for peripheral artery disease. Tβ4 has already shown wound healing and cardiac repair properties — CLI adds another compelling indication.

What This Study Doesn't Tell Us

Mouse CLI model — surgical ischemia may not fully replicate chronic human peripheral artery disease; lentiviral overexpression differs from peptide administration; group sizes not specified.

Questions This Raises

  • ?Would injectable Tβ4 protein (rather than gene therapy) achieve the same effects in CLI?
  • ?How does Tβ4-driven angiogenesis compare to VEGF gene therapy trials for CLI?
  • ?Could Tβ4 be combined with revascularization surgery for better outcomes?

Trust & Context

Key Stat:
Reversed pathway blockade Tβ4 overcame both Notch and NF-κB inhibition to restore angiogenesis, confirming pathway-specific mechanism
Evidence Grade:
Moderate — comprehensive in vitro and in vivo mechanistic study with pathway confirmation, but lentiviral delivery and unspecified group sizes.
Study Age:
Published in 2020; Tβ4 for cardiovascular indications continues in preclinical development.
Original Title:
Thymosin‑β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF‑κB pathway.
Published In:
International journal of molecular medicine, 46(4), 1347-1358 (2020)
Database ID:
RPEP-04973

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is critical limb ischemia?

The most severe form of peripheral artery disease where blood flow is so restricted that tissue death and gangrene occur, often requiring amputation if untreated.

How does thymosin β4 grow blood vessels?

It activates the Notch/NF-κB signaling pathway in blood vessel cells, which turns on VEGF and other growth factors that stimulate new blood vessel formation (angiogenesis).

Read More on RethinkPeptides

Cite This Study

RPEP-04973·https://rethinkpeptides.com/research/RPEP-04973

APA

Lv, Shumin; Cai, Hongwen; Xu, Yifei; Dai, Jin; Rong, Xiqing; Zheng, Lanzhi. (2020). Thymosin‑β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF‑κB pathway.. International journal of molecular medicine, 46(4), 1347-1358. https://doi.org/10.3892/ijmm.2020.4701

MLA

Lv, Shumin, et al. "Thymosin‑β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF‑κB pathway.." International journal of molecular medicine, 2020. https://doi.org/10.3892/ijmm.2020.4701

RethinkPeptides

RethinkPeptides Research Database. "Thymosin‑β 4 induces angiogenesis in critical limb ischemia ..." RPEP-04973. Retrieved from https://rethinkpeptides.com/research/lv-2020-thymosin-4-induces-angiogenesis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.